Congenital Ichthyosis – Market outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2021 To 2032
Congenital recessive ichthyoses are a heterogeneous group of disorders characterized clinically by scaling of the skin and histologically by the presence of a thickened stratum corneum. Most mutations are found in the TGM1 gene encoding transglutaminase 1, involved in forming the epidermal cornified cell envelope. ABCA12 encodes an ATP-binding cassette (ABC) transporter, involved in lipid transport, and ALOX12B, ALOXE3, and CYP4F22 code, respectively, for arachidonate 12(R)-lipoxygenase, arachidonate lipoxygenase-3, and cytochrome P450 protein, all involved in lipid metabolism. Symptoms include abnormally red, dry, and rough skin with large or fine white scales. The scales' appearance can vary; in some forms, the scales are fine and white, while in others, the scales are dark and brown, separated by deep cracks. The skin is also irritated. The skin on the palms of the hands and the soles of the feet can be very thick. Other complications can arise from more severe cases of ichthyosis. The skin loses moisture, becoming dry, tight, and inelastic. This rigidity can make movement difficult and cause the skin to crack and fissure. Walking becomes problematic when the skin on the soles of the feet thickens, and cracking around the fingers can make even simple tasks painful.
The prevalence of Congenital recessive ichthyoses
ranges from 1 to 2 cases in every 275,000 population in the USA.
The competitive
landscape of Congenital Ichthyosis includes country-specific approved and
pipeline therapies. Any asset/product-specific designation or review and
Accelerated Approval are tracked and supplemented with analyst commentary.
KOLs insights of Congenital
Ichthyosis across 8 MM market from the center of Excellence/ Public/ Private
hospitals participated in the study. Insights around current treatment
landscape, epidemiology, clinical characteristics, future treatment paradigm,
and Unmet needs.
Congenital
Ichthyosis Market
Forecast: Patient Based Forecast Model (MS. Excel Based Automated
Dashboard) which Data Inputs with sourcing, Market Event, and Product Event,
Country specific Forecast Model, Market uptake and patient share uptake,
Attribute Analysis, Analog Analysis, Disease burden, and pricing scenario,
Summary, and Insights.
S. No Asset Company Stage
1 TMB-001 Timber
Pharmceuticals LLC Phase 2
2 KB105 Krystal
Biotech, Inc. Phase 2
3 PAT-001 Patagonia
Pharmaceuticals, LLC Phase 2
4 ANB019 AnaptysBio,
Inc. Phase 2
5 146-9251 cream Crown
Laboratories, Inc. Phase 2
6 NS2 1% Aldeyra
Therapeutics, Inc. Phase 2
7 Afamelanotide Clinuvel
Pharmaceuticals Limited Phase 2
8 SXR1096 Sixera
Pharma Phase 2
Comments
Post a Comment